Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Functional Imaging in Hyperinsulinemic Hypoglycemia after Gastric Bypass Surgery for Morbid Obesity
Published in: Journal of Clinical Endocrinology and Metabolism
Access to document
10.1210/jc.2011-3063
Context: Hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass (RYGB) has been increasingly reported. It is induced by beta-cell hyperplasia often referred to as nesidioblastosis. Positron emission tomography (PET) with [11C]-5-hydroxytryptophan (C-11-HTP) and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine (F-18-DOPA) has been successfully applied to image neuroendocrine tumors. No data are available of the usefulness of these functional imaging techniques in post-RYGB in this new endocrine disorder, neither for diagnostic purposes nor for follow-up. Objective: We present a patient with post-RYGB hypoglycemia who underwent C-11-HTP and F-18-DOPA PET scintigraphy for diagnostic purposes and to evaluate...
Loek J. M. de Heide, Andor W. J. M. Glaudemans, Peter H. N. Oomen, Jan A. Apers, Eric R. E. Totte, Andre P. van Beek
PET/MRI in infectious and inflammatory diseases: will it be a useful improvement?
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-012-2060-9
Andor W. J. M. Glaudemans, Ana Maria Quintero, Alberto Signore
N-(4-F-18-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.111.091306
Interleukin-2 (IL2) binds with high affinity to the IL2 receptors overexpressed on activated T lymphocytes in various pathologic conditions. Radiolabeling of IL2 with a positron-emitting isotope could provide a tool for noninvasive PET of activated T cells in immune-mediated diseases. We report the labeling of IL2 with N-succinimidyl 4-F-18-fluorolbenzoate (F-18-SFB) for the synthesis of N-(4-F-18-fluorobenzoyl)interleukin-2 (F-18-FB-IL2) and the in vitro and in vivo evaluation of this novel radiopharmaceutical for the detection of IL2 receptor-positive cells by PET. Methods: F-18-SFB was efficiently prepared using a 3-step radiochemical pathway. Purified...
Valentina Di Gialleonardo, Alberto Signore, Andor W. J. M. Glaudemans, Rudi A. J. O. Dierckx, Erik F. J. De Vries
Good clinical practice and nuclear medicine
Published in: Trends on the role of PET in drug development
Access to document
10.1142/9789814317740_0025
Rationale for the use of radiolabelled peptides in diagnosis and therapy
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-011-2038-z
Nuclear medicine techniques are becoming more important in imaging oncological and infectious diseases. For metabolic imaging of these diseases, antibody and peptide imaging are currently used. In recent years peptide imaging has become important, therefore the rationale for the use of peptide imaging is described in this article. Criteria for a successful peptide tracer are a high target specificity, a high binding affinity, a long metabolic stability and a high target-to-background ratio. Tracer internalization is also beneficial. For oncological imaging, many tracers are available, most originating from regulatory...
K. P. Koopmans, A. W. J. M. Glaudemans